Browsing Tag
Sagimet Biosciences
2 posts
Sagimet’s acne strategy enters its biggest test after FDA clears denifanstat Phase 3
FDA clearance sends denifanstat into an 800-patient U.S. Phase 3 as Sagimet deploys its $257.6m cash base. See what the pivotal test means.
Can Sagimet turn denifanstat into a multi-indication platform and licensing engine beyond acne?
Can Sagimet parlay its acne win into a licensing engine and platform biotech story? Explore how FASN inhibition is being redefined across diseases.